1ef6436f35a68bf4.T1m1vF_w-vRWYl45jykt5HLNLjjfYvfaTeB-sruDFnM.PT3Z1CvDnNk9Jg9X10FAkj-iWWK3M5nuEoEY3_C2YyB8F9nXZ8i8oTNTGw
04-22 Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12 RE
03-24 Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders. CI
02-09 Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion. CI
22-03-13 KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation CI
22-02-24 KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation CI
21-11-25 Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021. CI
21-11-25 KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million. CI
21-11-25 KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million. CI
21-11-24 KAINOS Laboratories, Inc. authorizes a Buyback Plan. CI
20-11-25 Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020. CI
20-11-25 KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2020, has closed with 88,000 shares, representing 2.02% for ¥90.29 million. CI
20-11-25 KAINOS Laboratories, Inc. announces an Equity Buyback for 90,000 shares, representing 2.02% for ¥100 million. CI
20-11-24 KAINOS Laboratories, Inc. authorizes a Buyback Plan. CI
19-05-28 KAINOS Laboratories, Inc. announced that it has received ¥435.12 million in funding from Asahi Kasei Pharma Corporation CI
19-05-12 KAINOS Laboratories, Inc. announced that it expects to receive ¥435.12 million in funding from Asahi Kasei Pharma Corporation CI
18-09-25 Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on September 25, 2018. CI
18-09-25 KAINOS Laboratories, Inc.'s Equity Buyback announced on September 25, 2018 has expired with 490,800 shares, representing 11.01% for ¥541.35 million. The company repurchased 490,800 shares from Hitachi Chemical Company, Ltd.. CI
18-09-25 KAINOS Laboratories, Inc. announces an Equity Buyback for 500,000 shares, representing 11.22% for ¥551.5 million. CI
18-09-24 KAINOS Laboratories, Inc. authorizes a Buyback Plan. CI
16-02-09 Kainos Laboratories, Inc. announced that it has received ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm. CI
16-01-24 Kainos Laboratories, Inc. announced that it expects to receive ¥105.12 million in funding from Trust & Custody Services Bank, Ltd., Investment Arm. CI
15-08-25 Tranche Update on Kainos Laboratories, Inc.'s Equity Buyback Plan announced on August 25, 2015. CI
15-08-25 Kainos Laboratories, Inc.'s Equity Buyback announced on August 25, 2015, has expired with repurchase of 270,000 shares, representing 6.07% for ¥160.65 million. CI
15-08-25 Kainos Laboratories, Inc. announces an Equity Buyback for 300,000 shares, representing 6.74% for ¥210 million. CI
15-08-24 Kainos Laboratories, Inc. authorizes a Buyback Plan. CI

Become a member to access more news

New member
No results match your criteria
  1. Stock Market
  2. Stocks
  3. 4556 Stock
  4. News KAINOS Laboratories, Inc.